Issue 7, 2012

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

Abstract

Recently, the importance of targeted covalent inhibitors in addressing potency, selectivity and drug resistance has become of great interest, especially in the area of non-small cell lung cancer (NSCLC). Although several covalent EGFR TKIs that are advancing in NSCLC clinical development are active against mutations which are refractory to the reversible TKI drugs Tarceva and Iressa, limited chemical diversity has been explored; all of the irreversible and reversible clinical compounds share the same quinazoline scaffold. We describe the design of a novel pyrimidine-based irreversible inhibitor of EGFR (CNX17) which is active against both the WT EGFR as well as the resistance mutation L858R/T790M in biochemical assays. The inhibitor is also a potent inhibitor of EGFR signaling, including the L858R/T790M resistance mutation in cells (H1975 cell line, EC50 441 nM). Importantly, it also potently inhibits proliferation in both HCC827 (EGFRΔ746–750 EC50 < 5 nM) and H1975 (EC50 134 nM). This novel chemical scaffold may be an important addition to the armamentarium in overcoming drug resistance to current EGFR therapies.

Graphical abstract: Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

Supplementary files

Article information

Article type
Concise Article
Submitted
24 Jan 2012
Accepted
19 Apr 2012
First published
18 Jun 2012

Med. Chem. Commun., 2012,3, 780-783

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

J. Singh, E. Evans, M. Hagel, M. Labinski, A. Dubrovskiy, M. Nacht, R. C. Petter, A. Prasad, M. Sheets, T. St Martin, R. Tjin Tham Sjin, W. Westlin and Z. Zhu, Med. Chem. Commun., 2012, 3, 780 DOI: 10.1039/C2MD20017A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements